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Abstract
A major pathological hallmark of Alzheimer disease (AD) is the appearance in the brain of senile 
plaques that are primarily composed of aggregated forms of β-amyloid peptide (Aβ) that derive 
from amyloid precursor protein (APP). Posiphen (1) tartrate is an experimental AD drug in current 
clinical trials that reduces Aβ levels by lowering the rate of APP synthesis without toxicity. To 
support the clinical development of Posiphen (1) and elucidate its efficacy, its three major 
metabolic products, (+)-N1-norPosiphen (15), (+)-N8-norPosiphen (17) and (+)-N1, N8-
bisnorPosiphen (11), were required in high chemical and optical purity. The efficient 
transformation of Posiphen (1) into these metabolic products, 15, 17 and 11, is described. The 
biological activity of these metabolites together with Posiphen (1) and and its enantiomer, the AD 
drug candidate (−)-phenserine (2), was assessed against APP, α-synuclein and classical 
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cholinergic targets. All the compounds potently inhibited the generation of APP and α-synuclein 
in neuronal cultures. In contrast, metabolites 11 and 15, and (−)-phenserine (2) but not Posiphen 
(1) or 17, possessed acetylcholinesterase inhibitory action and no compounds bound either 
nicotinic or muscarinic receptors. As Posiphen (1) lowered CSF markers of inflammation in a 
recent clinical trial, the actions of 1 and 2 on proinflammatory cytokine interleukin (IL)-1β human 
peripheral bloodmononuclear cells was evaluated, and found to be potently inhibited by both 
agents.
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1. Introduction
Alzheimer’s disease (AD), a progressive neurodegenerative condition resulting in memory 
loss and neuropsychiatric disturbances, is the most common form of dementia. It accounts 
for some 64% of all dementias and afflicts more than 30 million people worldwide [1,2]. 
This number is expected to escalate to in excess of 37 million by 2025. Its economic burden 
and impact on the quality of life of both patients and their caregivers are overwhelming [1]. 
Existing therapeutic options available for AD remain limited and numerous recent AD 
experimental drugs have failed to demonstrate efficacy [3]. The only available approved 
drugs are three cholinesterase inhibitors (ChEIs): donepezil (Aricept, Eisai/Pfizer), 
rivastigmine (Exelon, Novartis), and galantamine (Reminyl, Janssen), and memantine, a 
NMDA glutamate receptor antagonist (Namenda, Merz/Forest) that is increasingly 
administered in combination with one of the ChEIs [4,5]. Whereas these agents have 
demonstrated functional improvements in behavioral and cognitive measures in mild to 
moderate AD, such clinical improvements are recognized to be only marginal. These drugs 
in combination or alone appear to ameliorate disease symptoms, but do not impact disease 
progression and provide only minimal cost-benefit tradeoffs [6].
A key pathological hallmark of AD is the appearance within brain of senile plaques that are 
largely composed of aggregated forms of amyloid-β peptide (Aβ), a predominantly 38 to 42 
amino acid length peptide that is derived from amyloid-β precursor protein (APP) following 
its proteolytic processing [2,7]. Numerous genetic associations between APP and familial 
AD (FAD) have focused APP into the center of AD research [7,8]. In general, FAD is 
accompanied by elevated levels of the longer Aβ42 form that readily aggregates to generate 
neurotoxic oligomers and fibrils that have been hypothesized to initiate a toxic cascade to 
eventually induce AD [2,7]. A further feature of AD is tau, a cytoplasmatic protein that 
binds to tubulin during its polymerization to, thereby, stabilize microtubules. Abnormal 
phosphorylation of tau results in the generation of aggregates (neuroﬁbrillary tangles) that, 
likewise, are toxic to neurons [9]. These pathological changes, which include synaptic loss, 
brain atrophy and neuroinflammation, likely occur over one or two decades prior to outward 
loss of intellectual capacity [1,2,7]. Soluble forms of Aβ oligomers have been found to target 
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synapses, impair memory, drive tau phosphorylation, induce oxidative stress and cause 
significant toxicity in both neuronal cultures and the brain of preclinical animal models, and 
hence represent a major target for drug development in AD treatment [1,2,7,8].
Strategies to reduce Aβ levels in brain primarily fall into two approaches and include those 
to increase its clearance, as achieved by both active and passive monoclonal antibodies 
against Aβ, and to lower the initial rate of Aβ generation [2,7]. To achieve the latter, drug 
design has primarily focused on the discovery of agents to inhibit the activities of either β- 
or γ-secretases, that are involved in the cleavage of APP to yield Aβ [2,7]. An alternative 
method to achieve the same aim is to reduce the synthesis of APP and, thereby, lower all its 
proteolytic products, including Aβ as well as N- and C-terminal fragments of APP, N-APP 
and C-31, that have likewise been reported to be neurotoxic [2,7].
Posiphen ((+)-phenserine) (1) tartrate is a small molecular weight (mw 487.5), lipophilic 
(Log D value 2.2) experimental AD drug that reduces Aβ levels by lowering the rate of APP 
synthesis without toxicity [9–11]. APP levels are endogenously regulated at both the 
transcriptional and post-transcriptional levels. Post-transcriptionally, APP mRNA is 
efficiently translated and can be regulated at the level of its 5’-untranslated region (5’-UTR). 
Posiphen (1) acts to lower the rate of APP synthesis via this 5’-UTR [11–13]. This translates 
into a concentration-dependent reduction in both APP protein as well as Aβ42 levels by up to 
50% in neuronal cultures and mice [10–12]. A key regulatory element within the 5’-UTR of 
APP mRNA is an iron response element (IRE) via which elevated brain iron concentrations 
and the proinflammatory cytokine interleukin-1β (IL-1β) are reported to up regulate [14], 
and Posiphen and (−)-phenserine to down regulate APP translation [11,13]. Importantly, this 
IRE stem loop structure is largely replicated within the 5’-UTR of α-synuclein mRNA [15] 
and similarly functions to confer iron dependent post-transcriptional control [16], thereby 
providing a means to potentially allow Posiphen (1) and (−)-phenserine (2) to lower α-
synuclein levels; an important target in Parkinson’s disease [17–19] for which drugs that 
impact disease progression also are lacking. Posiphen (1) has proved to be well tolerated in 
both rodents and dogs in preclinical toxicological studies and, likewise, was well tolerated in 
healthy elderly volunteers after oral dosing as well as in patients with mild cognitive 
impairment (MCI) [20]; widely considered to be an early promordal stage of AD. In these 
MCI studies 1 effectively lowered brain APP levels, as assessed by time-dependent analysis 
of CSF before and after Posiphen (1) administration [20], providing proof of mechanism of 
the agent as an APP synthesis inhibitor in humans. Interestingly, it likewise lowered both 
total and phosphorylated tau levels and markers on neuroinflammation [20].
Although Posiphen (1) lacks cholinesterase inhibitory activity [10] its dose-limiting action in 
humans (nausea and vomiting at 160 mg single dose administration [20]) could theoretically 
be cholinergically mediated. Ex vivo hepatocyte incubation studies of Posiphen (1) indicate 
that it generates the same three primary metabolites across rodents, dogs and humans, and 
initial pharmacokinetic studies in rodents and humans [20] confirm the presence of these 
same primary metabolites: the N-demethylated (+)-N1-norPoisphen (15), (+)-N8-
norPosiphen (17) and (+)-N1,N8-bisnorPosiphen (11). The reported acetylcholinesterase 
(AChE) inhibitory action of 15 (Table 1), in particular (IC50 63.4 ± 4.4 nM), may thereby 
provide Posiphen (1) indirect cholinergic action, mediated via its metabolism. By contrast, 
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the chiraly pure and separate drug (−)-phenserine (2), the antipodal isomer of Posiphen (1) 
(Figure 1), provides anticholinesterase activity as its primary action (AChE IC50 24.0±6.0 
nM) (Table 1) [21,22], but likewise reduces Aβ levels by lowering the rate of synthesis of 
APP in an equipotent manner to Posiphen (1) [10,11]. Additionally, compounds 1, 2, 11, 15 
and 17 could potentially possess muscarinic or nicotinic binding, which has not previously 
been measured but has been reported for (−)-physostigmine (18) [23–25]. (−)-Phenserine (2) 
has a lower maximally tolerated dose in humans (20 mg) [22] than Posiphen (1), reached 
phase 2/3 clinical trials in mild to moderate AD [26–28], and is currently being reformulated 
to optimize its clinical efficacy [29].
To support the clinical development of Posiphen (1) and elucidate it efficacy, the three 
primary metabolic products, (+)-N1-norPosiphen (15), (+)-N8-norPosiphen (17) and (+)-
N1,N8-bisnorPosiphen (11) are required in quantity with high chemical and chiral purity. 
Our generation of these allowed a comparative assessment of their AChE inhibitory 
activities versus our initial appraisal following the original synthesis of the compounds more 
than a decade ago (Table 1). In addition, we report their action to lower APP as well as α–
synuclein levels and describe their cholinergic binding activity and ability to lower the 
release of proinflammatory 1L-1β.
2. Results and discussion
2.1. Chemistry
Posiphen (1) is a phenyl carbamoyl analogue of (+)-physostigmine, and hence all methods 
allowing synthesis of the natural product, physostigmine (18), are technically useful in the 
preparation of Posiphen (1). Physostigmine (18) [30], a major alkaloid from Calabar beans, 
was first synthesized by Julian et al. [31] in 1935. Since that time, new synthetic routes have 
been continuously developed and published [32].
Our initial synthesis of Posiphen (1) was published in 1988, based on a modified Julian’s 
method [33,34]. In this, the separation of the enantiomers was accomplished by the 
introducition of a chiral center to form diasteromers, followed by chromatographic 
separation [35]. Alternatively, separation of the optical isomers can be achieved via the 
actions of D-camphorsulfonic acid and D-tartaric acid to provide the intermediate amine 
[31b]. Two further modified Julian’s syntheses for Posiphen (1) have been described: (i) 
where separation of racemic mixtures into the enantiomers was achieved on a preparative 
scale by use of a chiral stationary phase [36] and (ii) where the introduction of a chiral 
center was accomplished by phase transfer asymmmetric alkylation [37]. Each of these 
methods is valuable and practicable. However, in the event that synthesis of both 1 and 2 are 
desired concurrently, then the classical prime Julian method with modifications that permit 
separation of the (±)-intermediate amine by crystallization of salts of optically active organic 
acids to obtain both the (−)- and (+) enantiomers, is superior. In the event that Posiphen (1), 
alone, is required, then phase transfer would be preferable [37].
The total syntheses of N1,N8- bisnorPosiphen (11) [38], N1-norPosiphen (15) [37] and N8-
norPosiphen(17) [39] were separately published during 1998, 2003 and 1997, respectively. 
With plenty of clinical grade Posiphen (1) in hand as an available starting material, it was 
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unnecessary to obtain 11, 15 and 17 by total syntheses. The transformation of Posiphen (1) 
into these was therefore achieved as follows (Scheme 1, 2, 3), wherein the synthetic 
chemistry relating to Posiphen (1) and metabolites (11, 15 and 17) is, for the first time, 
brought together in a single place.
Posiphen (1) was transferred into (+)-eseroline (3) fumarate, in line with a known procedure 
used to successfully convert (−)-physostigmine (18) into (−)-eseroline [40]. Specifically, a 
butanol solution of 1 containing a catalytic amount of sodium was refluxed under strict 
nitrogen protection for 1 h. An equivalent hot butanol solution of fumaric acid was then 
added and, after cooling, almost quantitative fumarate of 3 was precipitated and collected by 
filtration.
Compound 3 was reacted with methyl iodide in the presence of KOH in DMSO to provide a 
N1-quaternary amine, 4, which, without isolation, was heated with benzyl bromide at 100 °C 
and stirred for appoximately 1 h to generate (+)-N1-benzylnoresermethole (5). This method 
was first utilized to allow the convertion of (−)-physostigmine (18) into (−)-physoverine [41] 
in which the quaternary amine was replaced by an oxygen atom by reaction with NaOH. The 
analytical data of 5 were identical to its known antipodal, with the exception that the optical 
rotation value was the opposite [42].
Compound 5 was transformed into compound 8 by O-demethylation and N-demethylation 
according to a procedure used in the synthesis of N1,N8-bisnorcymserine [43], with 
simplification. In this regard, the mixture of intermediates 6 and 7 was directly transferred 
into H1-benzyl-N8-noreseroline (8) in the absence of any tedious chromatographic 
separation step.
Reaction of compound 8 with phenyl isocyanate generated the required OH addition 
product, carbamate 9, or the unwanted NH addition compound, urea 10, depending on the 
specific catalytic conditions utilized. Specifically, to an ether solution of 8, a catalytic 
amount of Na was added, and then an equivalent of phenyl isocyanate was added with 
stirring at r.t.. Thereafter, the reaction mixture was continually stirred for 5 min, and a small 
amount of water was added to quench this reaction. Following isolation of the ether layer, 
routine work up provided the unwanted urea, 10, as a foam (90%). Alternatively, to the THF 
solution of compound 8 an equivalent of NaOEt was added and stirred until all solid was 
dissolved. Thereafter, the same procedure (as described above) yielded the required N1-
norcarbamate (9) as a foam (90%).
Debenzylation of compound 9 was accomplished by catalytical hydrogenation. In detail, the 
2-propanol solution of compound 9 with a catalytical amount of Pd(OH)2/C was placed in a 
hydrogenation bottle that was mounted on a hydrogenation apparatus and shaken overnight 
at r.t. to provide debenzyl compound 11. The alike procedure applied to unwanted 10 
resulted in generation of product 12. The treatment of 11 with D-tartaric acid provided the 
corresponding D-tartrate.
The transformation of compound 5 into N1-norPosiphen (15) was accomplished by a known 
procedure [37]. Specifically, 5 was treated with BBr3 in CH2Cl2 to generate (+)-N1-
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norbenzyl eseroline (13), which was subsequently reacted with equivalent phenyl isocyanate 
to provide phenyl carbamate (14). Debenzylation of compound 14 by catalytic 
hydrogenation, as described above, gave N1-norPosiphen (15) that then was transferred into 
its D-tartrate by the same procedure described for compound 11.
Posiphen (1) was oxidized by pyridinium dichromate (PDC) in CH2Cl2 to form N8-
norformyl crabamate (16), which then was reacted with HCl (10%) to provide N8-
norPosiphen (17), according to a known procedure for transformation of (−)-phenserine (2) 
into (−)-N8-norphenserine [39]. The D-Tartrate of 17 was obtained by treatment of base 17 
with D-tartaric acid, following the procedure described above.
2.2. Cholinesterase inhibitory activity, cholinergic receptor binding, and inhibitory APP, α-
synuclein and IL-1β action
Analyses of the IC50 values (50% inhibitory concentration) required to inhibit human AChE 
are shown in Table 1 for clinical grade Posiphen (1) and the newly prepared compounds 11, 
15 and 17, versus the literature values from our original sysntheses via the Julian route more 
than a decade ago. Notably, AChE preparations were generated from a freshly drawn blood 
sample provided by the exact same donor from which these enzyme were obtained to 
analyse the original synthesized compounds. Immediately noticable is the lack of activity of 
the measured Posiphen (1) sample against AChE, which is in accord with the lack of 
anticholinesterase action of (+)-physostigmine, versus the prior literature. A very minor 
contamination of 0.1% of the active chiral enantiomer, (−)-phenserine (2), within Posiphen 
(1) could readily account for the greater activity, albeit still low AChE action, in the 
literature value of 1. Based on this, the measured IC50 values of compounds 11, 15 and 17 
(Table 1) likely are a closer approximation of these agents’ true activities against AChE. 
Specifically, the (+)-N1-nor (15) and (+)-N1,N8-bisnorPosiphen (11) metabolites 
demonstrated AChE activity of possible clinical relevance that can be compared to both (−)-
phenserine (2) (IC50 18.6 nM) and donepezil (IC50 22 nM) [44], albeit metabolite 11 reaches 
only low levels in humans [20]. The measured AChE activity of 15 and 11 was slightly more 
potent versus data from our original syntheses (Table 1: measured vs. literature values), and 
the (+)-N8-Nor metabolite (17) was devoid of anticholinesterase action. Additionally, 
assessment against human butyrylcholinesterase (BChE) (not shown in Table 1), a sister 
enzyme to AChE that co-regulates brain acetylcholine levels and that may provide different 
actions in brain and prove a valuable target for AD [45–47] indicated a total lack of 
inhibitory action of Posiphen (1) and all metabolites (11, 15, 17) at this site, which is in 
accord with our original analyses [37,38].
In light of reports that (−)-physostigmine (18) [23–25] and, in particular, that (+)-
physostigmine [48] possess cholinergic agonist actions, compounds 1, 2, 11, 15 and 17 were 
assessed for binding to both muscarinic and nicotinic receptors subtypes (undertaken at the 
University of N Carolina, Chapel Hill, NC, Psychoactive Drug Screening Program). As 
shown in Table 2, the compounds lacked activity at all muscarinic (M1, M2, M3, M4, M5) 
and nicotinic (α2β2, α2β4, α3β2, α3β4, α4β2, α4β4) subtypes studied.
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Interestingly, as assessed at a single concentration of 5 uM in SH-SY5Y cell cultures, all 
three Posiphen primary metabolites (11,15,17), together with 1 and 2, lowered secreted APP 
levels (Table 1), which is in accord with the ability of 1 and 2 to lower APP in SH-SY5Y 
human neuroblastma cells at concentrations from 0.2 to 20 µM as well as in mice following 
their systemic administration [10]. A similar assessment of the ability of (−)-phenserine (2), 
Posiphen (1) and metabolites (11,15,17) to lower APP as well as α-synuclein levels was 
hence undertaken in primary cortical neuron cultures obtained from wild-type mice and α-
synuclein transgenic mice [49]. α-Synuclein is a ~15 kDa protein that can aggregate to form 
insoluble fibrils characterized by Lewy bodies in the pathogenesis of neurodegenerative α-
synucleinopathies [17], including the prevalent movement disorder Parkinson’s disease, in a 
manner similar to protein misfolding and aggregation of Aβ in AD [50]. Notably, α-
synuclein shares overlap in its 5’UTR with APP, particularly with regard to the presence of a 
unique RNA stem loop iron responsive element that mediates regulatory actions on its 
translation [15,16]. At a concentration of up to 1 uM 1, 2, 11, 15 and 17 induced a 
substantial decline (up to 70%) in both APP and α-synuclein protein levels in primary 
neuron cultures. Recent phase 1 Posiphen clinical trials in subjects with MCI in which levels 
of 1, 11, 15 and 17 were quantified in plasma and CSF suggest that concentrations in the 
order of 1–5 uM may be readily achievable in brain [20] and can effectively lower APP 
levels.
In light of the reduction in markers of neuroinflammation induced by Posiphen’s (1) within 
the CSF of clinical subjects with MCI [20] the abilites of 1 and 2 were assessed to inhibit the 
release of the proinflammatory cytokine IL-1β from freshly obtained peripheral blood 
mononuclear cells (PBMCs), as this cytokine is a prime initiator of inflammation, is elevated 
in AD [51], and elevated IL-1β levels are reported to heighten APP levels and its processing 
to Aβ [14]. In supernatants of PBMCs that were stimulated with phytohemagglutinin 
(PHA), IL-1β levels were significantly elevated by approximately two-fold, as assessed by 
ELISA. Posiphen (1) and (−)-phenserine (2) (0.1 to 10 uM) substantially (approx 50%) 
inhibited this IL-1β elevation. As shown in Figure 2, the mRNA expression of IL-1β was 
also assessed in freshly isolated PBMCs to define mechanisms responsible for the observed 
changes. Higher IL-1β mRNA expression was observed in PBMCs following PHA 
challenge that was largely normalized by both Posiphen (1) and (−)-phenserine (2).
In synopsis, (+)-N1-norPosiphen (15), (+)-N8-norPosiphen (17) and (+)-N1, N8-
bisnorPosiphen (11), generated by the described route, are currently being utilized to aid 
characterization as well as optimize the pharmacokinetics and pharmacodynamics of 
Posiphen (1) in animal and human studies to define its efficacy in the clinical treatment of 
AD. Posiphen (1), and particular metabolites possess a range of pharmacologic actions that 
include inhibition of APP, α-synuclein and IL-1β generation.
3. Conclusion
Posiphen (1), the opposite enantiomer of the distinct and separate anticholinesterase 
experimental AD drug (−)-phenserine (2) [10,21,26–28], has recently completed phase 1 
clinical trials and a proof of concept study in subjects with MCI and demonstrated brain 
entry and engagement of its primary target, APP. It appears to lower APP production in 
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subjects, as assessed within CSF, by as much as 50% [20]. Synthesis of Posiphen’s three 
major metabolic products, (+)-N1-norPosiphen (15), (+)-N8-norPosiphen (17) and (+)-N1, 
N8-bisnorPosiphen (11) indicates in the current study that APP lowering activity is shared 
by all, and hence this action in humans is likely mediated by the composite actions of the 
primary drug and its metabolites. Furthermore, this activity extends to the PD pathological 
protein, α-synuclein, for all agents as well as to (−)-phenserine (2). Additionally, Posiphen 
(1), and its opposite enantiomer, 2, limit IL-1β generation. Neither Posiphen (1) and 
metabolites (11, 15, 17) nor (−)-phenserine (2) possess muscarinic or nicotinic binding. 
However, 11 and 15, but not 1 or 17, have AChE inhibitory action, potentially providing 
Posiphen (1) indirect cholinergic action, albeit that Posiphen (1) time-dependently remains 
the primary drug species following its oral administration to humans followed by the 
generation of 17, 15, and only low levels of 11 (representing the percentages of the total area 
under the plasma time dependent curve of 52.6%, 24.1%, 19.8% and 3.4%, respectively) 
[20]. A recent study demonstrates that Posiphen (1) and metabolites (11, 15, 17) as well as 
(−)-phenserine (2) possess neuroprotective/neurotrophic actions at concentrations of clinical 
relevance [52]. These, together with the biological activities of the compounds described 
herein, provide Posiphen (1) and metabolites as well as phenserine (2) interesting 
pharmacological profiles that may prove beneficial in AD, MCI and PD on a number of 
levels.
4. Experimentals
4.1. Chemistry
Melting points (uncorrected) were measured with a Fisher-Johns apparatus. 1H NMR, 
and 13C NMR were recorded on a Bruker (Bellevica, MA) AC-300 spectrometer. MS (m/z) 
data were measured on an Agilent 5973 GC-MS (CI). Elemental analyses were performed 
by Atlantic Microlab, Inc. (Norcross, GA). All reactions involving non-aqueous solutions 
were performed under an inert atmosphere.
4.1.1. (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-ol (3)
—(+)-Posiphen (5g, 14.8 mmol) was dissollved in 40 ml of 1-butanol and a small piece of 
metal sodium (about 5 mg) added. After refluxing for 1 h in a nitrogen atmosphere, a hot 
butanol solution (32 ml) of fumaric acid (2g, 17.4 mmol) was added and stirred for 10 
minutes. The reaction mixture was left in the refrigerator overnight for complete 
crystallization. Filtration gave crystal (+)-eseroline fumarate (4.66 g 95%): mp, 
[α]d, 1HNMR were identical with literature [23].
4.1.2. (3aR)-1-benzyl-3a,8-dimethyl-5-methoxy-1,2,3,3a,8,8a-
hexahydropyrrolo[2,3-b]indole (5)—Compound 3 (2.89 g, 13.2 mmol) was dissolved in 
DMSO (15 ml), and KOH powder (2.22 g, 39.6 mmol) was added. The reaction mixture was 
stirred and cooled by a water bath, and MeI (3.76 g, 26.5 mmol) was added and stirred for 
0.5 h. Thereafter, a further portion of MeI (3.76 g, 26.5 mmol) was added and the reaction 
mixture was stirred at r.t. for an additional 0.5 h. Finally, all excess MeI was removed by 
vacumm evaporation. Benzyl amine (2.84 g, 26.5 mmol) was added to the reaction mixture, 
which then was placed into an oil bath and, during stirring, was heated to 100°C for 1 h. 
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Following cooling, 25 ml of water was added and the mixture was extracted by ether (3 x 20 
ml). The extracted solution was washed with brine, dried over NaSO4 and concentrated to 
provide a residue that was crystallized from MeOH to obtain crystalline compound 5 (3.26 
g, 80%): mp [α]d23 = +52.0° (c = 0.1, CHCl3). The 1HNMR and MS were identical with 
that of it’s known enantiomer [42].
4.1.3. (3aR)-1-benzyl-3a-methyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-ol 
(8)—To a solution of 5 (3.08g, 0.01 mol) in CH2Cl2 (150 ml) was added NaHCO3 (2 g). The 
mixture was stirred vigorously and cooled in an ice bath. Pyridinium dichromate (PDC) 
(7.52 g, 0.02 mol) was then added, and the mixture maintained with stirring over an ice bath 
for 2 h. The reaction mixture was, thereafter, filtered and the resulting solid was washed with 
CH2Cl2 (100ml). This combined CH2Cl2 solution was then washed with water (3 x 100 ml), 
dried over Na2SO4 and concentrated under vacuum. The residue was purified by column 
chromatography (silica gel, petroleum ether : ethyl acetate = 4 : 1) to remove unreacted 5, as 
the fastest component, and pyridine, as slowest component, to generate a mixture of 6 and 7 
(1.8g). Prepared TLC afforded a small amount of pure 6 and 7, sufficient to acquire H1NMR 
and MS data that proved to be identical to that of their enantiomers reported in the literature 
[43]. This mixture of 6 and 7 was subsequently dissolved in CH2Cl2 (150 ml) and BBr3 (10 
g, 0.04 mmol) in CH2Cl2 (15 ml), and was added dropwise with stirring and cooling by a 
water bath. Thereafter, the mixture was stirred for 1 h at r.t., followed by evaporation of 
solvent and BBr3 under vacuum. To this residue, MeOH (50 ml) was slowly added during 
stirring and cooling in a water bath, and the mixture was thereafter stirred for a further 0.5 h 
at r.t. Evaporation of solvent provided a residue that was then dissolved in H2O (100 ml). To 
the water solution, ether (200 ml) and a saturated aqueous solution of Na2CO3 (100 ml) was 
then added. This mixture was stirred overnight until the entire solid complex was hydrolyzed 
and the base dissolved within the ether layer. This ether layer was separated, and the 
aqueous layer was then washed with fresh ether (2 x 100 ml). The combined ether solution 
was then dried over Na2SO4, and concentrated under vacuum to provide a residue that next 
was dissolved into dry THF (100 ml). To this THF solution, NaBH4 (1.4 g, 0.037 ml) was 
added and then stirred in excess of 5 h at r.t. until the reddish color of the reaction mixture 
gradually changed to a clear light yellow, and a single spot was evident under TLC. 
Thereafter, water (40 ml) was added and stirred for approximately 20 min to dissolve solid 
material. The mixture was subsequently extracted by ether (3 x 150 ml), and the combined 
extract was then dried over Na2SO4. Evaporation of solvent gave product 8 as a foam (1.12 
g, 40%). The 1HNMR and MS of 8 proved to be identical with that of it’s known enantiomer 
[43] with the optical rotation providing the expected opposite value.
4.1.4. (3aR)-1-benzyl-3a-methyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl 
N-phenyl carbamate (9)—To the solution of compound 8 (280.4 mg, 1.0 mmol) in THF 
(8 ml), NaOAc (82 mg, 1.0 mmol) was added. After stirring for 5 minutes, phenyl isocyanate 
(107 mg, 0.9 mmol) was added dropwise. The mixture was then stirred at r.t. for 10 minutes, 
and 1.0 ml of water was added to quench the reaction. The reaction mixture was partitioned 
into ether and water, the organic layer was washed with water, brine, and dried over Na2SO4. 
Evaporation of solvent gave a crude product that was directly chromatographed (silica gel, 
EtOAc / petroleume ether = 1/3) to give compound 9 (359mg, 90%) as a foam: 1HNMR 
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(CDCl3) δ 7.50–7.10 (m, 10H, Ar-H), 6.85 (s, 1H, C4-H), 6.78 (dd, J = 1.7, 8.5 Hz, 1H, C6-
H), 6.50 (d, J = 8.5 Hz, 1H, C7-H), 4.54 (s, 1H, C8a-H), 3.85–3.90 (m, 2H, CH2-Ph), 2.70–
2.80 (m. 2H, C2-H2), 1.90–1.80 (m, 2H, C3-H2), 1.45 (s, 3H, C3a-CH3) ppm; CI-MS (CH4), 
m/z: 281(MH+-PhNCO), 120 (PhNCO+1).
4.1.5. (3aR)-1-benzyl-5-hydroxy-3a-methyl-N-phenyl-1,2,3,3a-
tetrahydropyrrolo[2,3-b]indole-8(8aH)-carboxamide (10)—To the solution of 
compound 8 (280.4 mg, 1.0 mmol) in ether (8 ml), a piece of metal Na (about 1 mg) was 
added. After stirring 5 minutes, phenyl isocyanate (107mg, 0.9 mmol) was added dropwise. 
The mixture was again stirred at r.t. for 10 minutes, and 1.0 ml of water was then added to 
quench the reaction. After washing the reaction mixture with water and brine, and drying 
over Na2SO4, evaporation of solvent provided a crude product that was directly 
chromatographed (silica gel, EtOAc / petroleume ether = 1/3) to give compound 10 (359 mg, 
90%) as a foam: 1HNMR (CDCl3) δ 8.82 (s, 1H, 7.50–7.10, urea NH), 7.80–6.60 (m, 13H, 
Ar-H), 5.08(s, 1H, C8a-H), 4.10 and 3.90 (AB, J=16.6 Hz, 2H, CH2-Ph), 2.90 (m. 2H, C2-
H2), 2.25 (m, 1H, C3-Ha), 2.00 (m, 1H, C3-Hb), 1.65 (s, 3H, C3a-CH3) ppm; CI-MS (CH4), 
m/z: 281(MH+-PhNCO), 120 (PhNCO+1).
4.1.6. D-Tartrate of (3aR)- 3a-methyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-
b]indol-5-yl N-phenyl carbamate (11)—A solution of compound 9 (100 mg, 0.25 
mmol) in 2-propanol (5 ml) and Pd(OH)2/C (10 mg) was placed into a hydrogenation bottle, 
which then was shaken in 40 psi at r.t. overnight. After the catalyst was filtered through 
celite, the filtrate was concentrated to provide a residue that was chromatographed (silica 
gel, CH2Cl2 / MeOH = 10 : 1) to generate compound 11 ( 62 mg, 80%). Compound 11 and 
an equivalent amount of D-tartaric acid then were dissolved in methanol, and evaporation of 
solvent gave a residue that was crystallized from ether to give the D-tartrate of compound 
11: m.p. 105–110 °C; [α]d23 = +66.6° (c = 0.1, acetone : H2O = 1:1); 1HNMR (CDCl3) δ 
10.02 (s, 1H, NH), 7.50 (d, J=8.5Hz, 2H, 2C2’-H), 7.30 (t, J=8.5Hz, 2H, 2C3’-H), 7.04 (s, 
1H, C4-H), 7.00 (dd, J=1.7, 8.5Hz, 1H, C4’-H), 6.85 (d, J=8.5Hz,1H, C6-H), 6.60 (d, J = 8.5 
Hz, 1H, C7-H), 5.10 (s, 1H, C8a-H), 3.27 (m. 1H, C2-Ha), 2.75 (m. 1H, C2-Hb), 2.10 (m, 
1H, C3-Ha), 2.04 (m, 1H, C3-Hb), 1.40 (s, 3H, C3a-CH3) ppm. Anal. Calc. for C18H19N3O2. 
2C4H6O6. H2O. 0.2Et2O: C, 50.11; H, 5.49; N, 6.54. Found: C, 50.20; H, 5.80; N, 6.90.
4.1.7. D-tartrate of (3aR)-5-hydroxy-3a-methyl-N-phenyl-1,2,3,3a-
tetrahydropyrrolo[2,3-b]indole-8(8aH)-carboxamide (12)—Following a similar 
procedure involved in the generation of compound 11 from 9, hydrogenative debenzylation 
of compound 10 provided compound 12 (80%) that then, likewise following the same 
procedure, was transferred to its D-tartrate: m.p. 132–136 °C; [α]d23 = −27.0° (c = 0.1, 
acetone : H2O = 1:1); 1HNMR (CDCl3) δ 9.05 (s, 1H, NH), 7.45 (d, J=8.5Hz, 1H, C7-H), 
7.30 (d, J=8.5Hz, 2H, 2C2’-H), 7.10 (dd, J=1.7, 8.7Hz, 2H, 2C3’-H), 6.80 (dd, J=1,7, 8.5Hz, 
1H, C4’-H), 6.50 (s, 1H, C4-H), 6.40 (d, J=8.5Hz,1H, C6-H), 5.15 (s, 1H, C8a-H), 2.90 (m. 
1H, C2-Ha), 2.30 (m. 1H, C2-Hb), 1.85 (m, 1H, C3-Ha), 1.68 (m, 1H, C3-Hb), 1.22 (s, 3H, 
C3a-CH3) ppm. Anal. Calc. for C18H19N3O2. 1.6 C4H6O6: C, 53.33; H, 5.25; N, 7.65. 
Found: C, 53.24; H, 5.20; N, 7.69.
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4.1.8. D-Tartrate of (3aR)- 3a,8-dimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-
b]indol-5-yl N-phenyl carbamate (15)—Following a procedure within the literature 
[37], demethylation of compound 5 provided compound 14 (85%) that then was reacted with 
phenylisocyanate to generate compound 15 (90%). Utilizing the described methods to 
synthesize compound 11 from 9, hydrogenative debenzylation of 14 gave compound 15 
(80%) that then was transferred in to its D-tatrate as similarly delatailed above : m.p. 126–
127 °C; [α]d23 = +56.8° (c = 0.4, EtOH); 1HNMR (CDCl3) δ 10.02 (s, 1H, NH), 7.55 (d, 
J=8.5Hz, 2H, 2C2’-H), 7.35 (t, J=8.5Hz, 2H, 2C3’-H), 7.10 (s, 1H, C4-H), 7.10 (m, 1H, 
C4’-H), 6.95 (d, J=8.5Hz,1H, C6-H), 6.55 (d, J = 8.5 Hz, 1H, C7-H), 4.88 (s, 1H, C8a-H), 
3.27 (m. 1H, C2-Ha), 2.75 (m. 1H, C2-Hb), 2.15 (m, 1H, C3-Ha), 2.04 (m, 1H, C3-Hb), 1.45 
(s, 3H, C3a-CH3) ppm. Anal. Calc. for C19H21N3O2. 2.4C4H6O6.H2O: C, 48.96; H, 5.17; N, 
5.99. Found: C, 48.99; H, 4.99; N, 6.38.
4.1.9. D-Tartrate of (3aR)-1,3a-dimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-
b]indol-5-yl N-phenyl carbamate (17)—In accord with a procedure within the literature 
[39], oxidation of posiphen (1) gave compound 16 (35%) that then was reacted with HCl 
(10%) to provide compound 17 (70%). As described above, this then was transferred into its 
D-tartrate: m.p. 119–120°; [α]d23 = + 46.7ο (c = 0.4, EtOH); 1HNMR (CDCl3) δ 10.05 (s, 
1H, NH), 7.52 (d, J=8.5Hz, 2H, 2C2’-H), 7.32 (t, J=8.5Hz, 2H, 2C3’-H), 7.10 (m, 1H, C4’-
H), 7.00 (s, 1H, C4-H), 6.80 (d, J=8.5Hz,1H, C6-H), 6.55 (d, J = 8.5 Hz, 1H, C7-H), 4.60 (s, 
1H, C8a-H), 2.95 (m. 1H, C2-Ha), 2.75 (m. 1H, C2-Hb), 2.02 (m, 2H, C3-H2), 1.40(s, 3H, 
C3a-CH3) ppm. Anal. Calc. for C19H21N3O2. 1.5C4H6O6: C, 54.75; H, 5.51; N, 7.66. 
Found: C, 54.67; H, 5.88; N, 7.42.
4.2 Quantification of biological action
4.2.1. Anticholinesterase activity—The anticholinesterase activity of compounds 
1,2,11,15 and 17 was assessed by quantifying their capacity to inhibit the ability of freshly 
prepared human AChE and BChE to enzymatically cleave their respective selective 
substrates, acetyl-(β-methyl)thiocholine and s-butyrylthiocholine (0.5 mmol/L) (Sigma 
Chemical Co., St. Lois, MO) [37–39]. Samples of AChE and BChE were prepared from 
freshly collected human erythrocytes and plasma, respectively. Compounds were dissolved 
in and then were diluted in 0.1 M Na3P04 buffer (pH 8.0) in half-log concentrations to 
provide a final concentration range that spanned 0.3 nM to 10 uM.
For the preparation of BChE, freshly collected blood was centrifuged (10,000 g, 10 min, 4° 
C) and plasma was separated and diluted 1:125 with 0.1 M Na3P04 buffer (pH 7.4). An 
absence of haemolysis was verified within the plasma to ensure no contamination with 
AChE. For AChE preparation, erythrocytes were washed five times in isotonic saline, lysed 
in 9 volumes of 0.1 M Na3P04 buffer (pH 7.4) containing 0.5% Triton-X (Sigma) and 
thereafter were diluted with an additional 19 volumes of buffer to a final dilution of 1:200.
Analysis of anticholinesterase activity was undertaken by utilizing a 25 µL sample of each 
enzyme preparation at their optimal working pH, 8.0 in 0.1 M Na3P04 buffer (0.75 mL total 
volume). 1,2,11,15 and 17, alongside (−)-physostigmine (18) as an external control, were 
preincubated with enzymes (30 min, r.t.) and then were incubated with their respective 
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substrates and with 5,5’-dithiobis-2-nitrobenzoic acid (25 min, 37° C). The substrate/
enzyme interaction was immediately halted by the addition of excess (−)-physostigmine (18) 
(1 x 10−5 M) and production of a yellow thionitrobenzoate anion was then measured by 
spectrophotometer at 412 nm λ. To correct for nonspecific substrate hydrolysis, aliquots 
were co-incubated under conditions of absolute enzyme inhibition (achieved by 1 x10−5 M 
(−)-physostigmine (18)), and the associated alteration in absorbance was subtracted from 
that observed throughout the concentration range of each test compound. All agents were 
analyzed on a minimum of three separate occasions, each in duplicate. The mean enzyme 
activity at each concentration of compounds 1,2,11,15 and 17 was then expressed as a 
percent of the activity in the absence of compound. This was transformed into a logit format 
(in which logit = ln(%activity/100 minus %activity)) and then was plotted as a function of its 
log concentration. Anticholinesterase activity was determined as an IC50, defined as the 
concentration of compound (nM) required to inhibit 50% of enzymatic activity, as 
determined from a correlation between log concentration and logit activity. Results deriving 
from correlation coefficients of r2 ≥ −0.98 were considered acceptable, any not achieving 
this threshold were repeated.
4.2.2. APP and α-synuclein activity—Human SH-SY5Y neuroblastoma cells were 
acquired from from the American Type Culture Collection (Manassas, VA) and cultured as 
previously described [10,53,54]. Cells were grown in complete media (10% fetal calf serum, 
2 mM glutamine in DMEM and an antibiotic cocktail (Invitrogen)) to 70% confluence. 
Thereafter, spent media was removed and replaced with fresh media (DMEM) containing 
experimental drug. Primary neurons cultures from the cortices of PAC-Tg(SNCA) and wild 
type mice embryos were prepared from embryonic day 15 to 18 mice as previously 
described [55]. The PAC-Tg(SNCA) transgenic mice express the human SNCA gene 
translated via the bonafide SNCA 5’UTR [49,54]. Cortices were removed, dissected free of 
meninges, and dissociated in 0.025% trypsin. Cortical cells were plated onto poly-L-lysine 
(50 ug/ml)-coated 12-well or 48-well plates (Nunc) at a density of 600,000 cells/cm2) in 
DMEM supplemented with 10% FCS, 5% HS, and 10ug/ml gentamycin sulfate. The 
neurons were allowed to adhere for 2–3 hr before the plating medium was replaced with 
Neurobasal supplemented medium (serum free and with B27 minus antioxidants, 500 uM 
glutaMAX and 10 ug/ml gentamycin sulfate). Neuronal purity of cultures was in the order of 
90%–95%. On the day of experiments the medium was replaced with fresh Neurobasal-
supplemented medium and for all further experimentation the medium was serum-free. Cells 
were challenged with compounds 1,2,11,15 and 17 (SH-SY5Y cells 5 uM, primary neurons 
1 uM – and lower concentrations) overnight and probed for either APP or α-synuclein 
expression, as descibed previously [10,54]. Western immunoblotting was undertaken with 
either monoclonal mouse-anti-APP (22C11; Millipore, Billerica, MA) or mouse monoclonal 
anti-α-synuclein (BD Transduction Laboratories, Lexington, KY), and monoclonal mouse-
anti-β-actin (Sigma) was utilized as an internal control. Thereafter, blots were probed with 
the appropriate horseradish peroxidase-conjugated antibody (Pierce, Rockford, IL) and 
detected by ECL techniques (GE Healthcare, Piscataway, NJ).
4.2.3. Cholinergic receptor binding—The receptor binding profiles of 1,2,11,15 and 17 
were generously provided by the National Institute of Mental Health’s Psychoactive Drug 
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Screening Program (Contract # HHSN-271–2008-00025-C (NIMH PDSP). The NIMH 
PDSP is directed by Bryan L. Roth M.D., Ph.D at the University of North Carolina at 
Chapel Hill and Project Officer Jamie Driscol at NIMH, Bethesda MD, USA). For 
experimental details please refer to the PDSP web site http://pdsp.med.unc.edu/ (click on 
“Binding Assay”).
Briefly, binding to human muscarinic receptors, M1, M2, M3, M4, M5, was assessed in 
stably transfected cell lines in muscarinic binding buffer (50 mM Tris-HCl, pH 7.7) in 
quadruplicate using a protocol adapted from Ernsberger and colleagues [56]. For all 
muscarinic subtypes, [3H]QNB ([3H]quinuclidinyl benzilate) (final concentration 0.5 nM) 
was used as the radiolabel and atropine (10 pM to 10 µM) as the reference compound in a 
96-well plate format. Membrane fractions of cells expressing recombinant targets were 
added together with test compounds (10 µM), 250-µL reactions were incubated at room 
temperature (shielded from light) for 1.5 hours, that then were harvested by rapid filtration 
onto Whatman GF/B glass fiber filters pre-soaked with 0.3% polyethyleneimine using a 96-
well Brandel harverster. Four rapid 500-µl washes were performed with chilled standard 
binding buffer to reduce non-specific binding. Filters were placed in 6-ml scintillation tubes 
and allowed to dry overnight. Thereafter, 4 ml of EcoScint scintillation cocktail (National 
Diagnostics) was added to each tube that was capped, labeled, and counted by liquid 
scintillation counting.
In a similar manner, binding of test compounds (10 µM) was assessed to human nicotinic 
receptors, α2β2, α2β4, α3β2, α3β4, α4β2, α4β4, in quadruplicate using an assay adapted 
from Xiao and colleagues [57]. For all nicotinic subtypes, [3H]-epibatidine (final 
concentration 0.5 nM) was used as the radiolabel and (−)-nicotine (10 pM to 10 µM) as the 
reference compound.
4.2.4 Separation of peripheral blood mononuclear cells, challenge with PHA 
and assessment of IL-1β release—The Separation and stimulation of PBMCs was 
performed as described elsewhere [58]. The PBMC fraction was obtained by density 
centrifugation of diluted blood (1 part blood to 1 part pyrogenfree saline) over Ficoll-Paque 
(GE Healthcare, EuroClone, Pero (MI) Italy). PBMCs were washed twice in saline and 
suspended in culture medium (RPMI-1640, Sigma) supplemented with 10% fetal calf serum, 
L-glutamine, and PES (Sigma, St. Louis, MO). The cells were counted and their 
concentration was adjusted to 1x 106 cells/ polypropylene round-bottom tube (Becton 
Dickinson, Franklin Lakes, NJ). Cell viability, assessed by Trypan blue dye exclusion, was 
not significantly influenced by the cell culture conditions, and more than 98% of PBMCs 
were viable at the end of incubation. After a 24 hr incubation at 37°C, in the presence an 
absence of PHA (20 µg/ml (Sigma/Aldrich) – a dose chosen for its ability to aspecifically 
induce release of proinflammatory cytokines) cell-free supernatants were removed and 
stored at −80°C until assay, and pelleted cells were similarly kept until analysis. IL-1β 
concentration in culture supernatants was determined by a solid phase sandwich ELISA kit 
with monoclonal anti-human IL-1β (Endogen, Woburn, MA, USA).
Total RNA was extracted from PBMC cell cultures using TRIzol reagent (Invitrogen, Life 
Technologies, Paisley, U.K.), according to the manufacturer’s protocol. The RNA 
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concentration was estimated by measuring the absorbance at 260 nm λ using a Bio-
Photometer (Eppendorf AG, Hamburg, Germany), and RNA samples were kept frozen at –
80 °C until use. Purified RNA was electrophoresed on a 1% agarose gel to assess the 
integrity of the purified RNA. One microgram of RNA was reverse transcribed into cDNA 
using a High Fidelity Superscript reverse transcriptase commercially available kit (Applied 
Biosystems, Foster City, CA, USA), in accord with the manufacturer’s instructions. mRNA/
cDNA specific cytokine primer pairs were designed and PCR was performed, as described 
previously [58].
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Abbreviations
(SNCA) α-Synuclein gene
(AChE) Acetylcholinesterase
(AD) Alzheimer’s disease
(Aβ) amyloid-βpeptide
(APP) amyloid-βprecursor protein
(BChE) butyrylcholinesterase
(ChEIs) cholinesterase inhibitors
(DMSO) dimethylsulfoxide
(EtOAc) ethyl acetate
(FAD) familial Alzheimer’s disease
(FCS) fetal calf serum
(IL-1β) interleukin-1β
(IRE) iron response element
(MS) mass spectroscopy
(MeOH) methanol
(MeI) methyl iodide, also called iodomethane
(MCI) mild cognitive impairment
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(NMR) nuclear magnetic resonance
(Pd(OH)2/C) Pearlman’s catalyst
(PBMCs) peripheral blood mononuclear cells
(PHA) phytohemagglutinin
(PDC) pyridinium dichromate
(QNB) quinuclidinyl benzilate
(NaOEt) sodium ethoxide
(THF) tetrahydrofuran
(TLC) thin layer chromatography
(5’-UTR) 5’-untranslated region
(IC50) value 50%inhibitory concentration
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Figure 1. 
Chemical strucures of Posiphen (1), (-)-phenserine (2) and (-)-physostigmine (18).
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Figure 2. 
human peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll-Hypaque 
density gradient centrifugation, maintained in cell culture and were then challenged with 
PHA (20 µg/ml). The mRNA levels of IL-1β normalized to those 18S mRNA in the 
corresponding samples are shown. Additionally, not shown, IL-1β levels were measured 
with commercially available ELISA kits, were elevated by PHA and ameliorated by 
Posiphen (1) and phenserine (2).
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Scheme 1. 
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Scheme 2. 
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Scheme 3. 
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